Virex Pharma Ltd Announces Completion of In Vitro Studies for Revolutionary Inhaled Antiviral Treatment for RSV
Virex Pharma Ltd (Virex), an innovative biopharmaceutical company specialising in antiviral therapies, is pleased to announce the successful completion of in vitro studies for its unique inhaled antiviral nanoemulsion treatment for Respiratory Syncytial Virus (RSV). The results have shown promising efficacy and safety profiles, marking a significant milestone in the development of a potential breakthrough therapy for RSV.
RSV is a highly contagious respiratory virus which worldwide affects 33 million individuals of all ages, with a particular impact on infants, young children, older adults, and immunocompromised individuals. It is a major cause of bronchiolitis and pneumonia, leading to 3 million hospitalisations and 60,000-200,000 in-hospital deaths in children aged under 5 years, worldwide. RSV has been a challenging infection with the market projected to be c. US$4Bn in 2027. Despite the urgent need for effective treatments, there are currently limited therapeutic options available.
Our latest results have indicated GlyXine, Virex Pharma’s proprietary antiviral nanoemulsion has a therapeutic index which is significantly higher than those reported by Ventolin and other inhaled corticosteroid products. This provides additional reassurance of the potential safety of the GlyXine product. GlyXine, has exhibited remarkable potential in inhibiting RSV replication within human cells. The in vitro results provide a strong foundation for further development and pave the way for upcoming animal trials.
“We are extremely encouraged by the results of the in vitro studies, which demonstrate the antiviral activity and safety profile of GlyXine” said Ms. Rolee Kumar, Chief Executive Officer of Virex. “RSV poses a significant public health challenge, particularly for vulnerable populations. Our innovative inhaled antiviral treatment has the potential to transform the treatment landscape for RSV, offering a targeted and convenient therapeutic option.”
Virex is dedicated to advancing the development of GlyXine through rigorous scientific research and clinical investigations. The company’s team of accomplished scientists, researchers, and clinicians are committed to bringing this potentially life-changing therapy to patients in need.
With the completion of the in vitro studies, Virex will now focus on initiating comprehensive preclinical and clinical studies to evaluate the safety, efficacy, and tolerability of GlyXine in animals and human subjects. These pivotal trials will provide crucial insights into the therapeutic potential of Virex’s innovative inhaled antiviral treatment for RSV.
Virex remains steadfast in its commitment to making a meaningful impact on global public health by developing innovative antiviral therapies. The company will continue to collaborate with leading experts, regulatory authorities, and stakeholders to expedite the development and potential regulatory approval of GlyXine, bringing hope to millions affected by RSV worldwide.
For media inquiries or further information, please contact:
[Ms Rolee Kumar roleek@virexpharma.com]
About Virex:
Virex is an innovative biopharmaceutical company dedicated to developing antiviral therapies for infections caused by RSV, COVID-19 and Dengue viruses. With a focus on addressing critical unmet medical needs, Virex’s research and development efforts aim to revolutionise the treatment landscape for viral infections. Through cutting-edge science, rigorous clinical investigations, and strategic partnerships, Virex strives to bring breakthrough therapies to patients worldwide.
